Phase 2 Liver Cancer Trial, Recruiting NCT07145801 Sponsor: Thomas Jefferson University Condition: Liver Cancer
Back to Liver Cancer

Phase 2 Liver Cancer Trial, Recruiting

NCT07145801
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are scheduled to receive a specific type of liver-targeted radiation treatment (called TARE) for liver cancer that has not been treated before and can be seen on an ultrasound scan.
  • You are at least 18 years old.
  • You are in a generally stable condition of health.
  • If you are a woman who could become pregnant, you must have a negative pregnancy test.
  • You have read, understood, and signed a consent form agreeing to take part in the study.

Who may not be able to join:

  • You are in an unstable, seriously ill, or terminally ill condition, or your health situation is difficult to predict.
  • You have a known allergy or sensitivity to any of the ingredients in a contrast agent called Lumason (used during ultrasound).
  • You have a known allergy or sensitivity to any of the ingredients in a contrast agent called Sonazoid (used during ultrasound).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Thomas Jefferson University
Registry
ClinicalTrials.gov
Start date
11 September 2025
Est. completion
30 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Tumor viability on contrast enhanced ultrasound using a blood pooling contrast agent; Tumor viability on contrast enhanced ultrasound using a blood pooling contrast agent

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov